Recent Health releases

Wellbeing a ‘work in progress’ for most UK HR departments

[PRESSWIRE] London, United Kingdom - 11 June, 2018 -- A study conducted by Cascade has revealed that only 13% of HR/business managers believe their organisation has an effective wellbeing strategy in place. 67% admit that it is ‘a work in progress’.

Klotho and endocrine FGFs: More than markers of CKD progression and cardiovascular complications

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- Klotho, the Greek goddess who spins the thread of life, has become popular among nephrologists, because the genes named after her encode receptors for hormones that play critical roles in the pathophysiology of chronic kidney disease (CKD). Namely, αKlotho and βKlotho function as receptors for two hormones, fibroblast growth factor-23 (FGF23) and FGF21, respectively. 

DKK3: A novel diagnostic tool for improving the management of CKD patients and thus to mitigate the future burden of CKD

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- The prevalence of chronic kidney disease (CKD) is relatively high, at approximately 10% of the population, but only relatively few patients have endstage renal disease and require renal replacement therapy.

A pre-emptive kidney transplant is still the best option for patients with kidney failure

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- A new analysis [1], published in Nephrology Dialysis Transplantation during this week’s ERA-EDTA Congress in Copenhagen, confirms that a kidney transplant before start of dialysis extends the life of both the patient and the transplanted organ. However, for patients who do not receive a preemptive transplant, the length of time they spend dialysis (dialysis vintage) no longer appears to reduce their life expectancy after transplantation.

Addressing cardiovascular risk factors can help to improve access to, and outcomes of, kidney transplantation

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- A review [1] published in Nephrology Dialysis Transplantation (NDT) during the ERA-EDTA Congress in Copenhagen highlights the importance of controlling all metabolic risk factors for cardiovascular disease in every potential kidney transplant candidate, both before and after transplantation.

Can ferric citrate improve the outcome of predialysis patients?

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- A late breaking clinical study [1] at the ERA-EDTA Congress in Copenhagen showed that the phosphate binder ferric citrate improves multiple aspects of abnormal mineral metabolism and raises hemoglobin in patients with advanced chronic kidney disease (CKD), who do not have abnormal levels of blood phosphate or anemia. 

ERA-EDTA is the first medical association that invests in ‘greener’ healthcare!

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- The ERA-EDTA is the leading society in Europe for physicians working in the field of care for patients with kidney disease – and is the first medical association to try and implement ‘greener’ health care as suggested by the ‘Lancet Countdown’. Technical progress, e-health, the support of home and self care schemes and sustainable healthcare education and research are ways to ‘greener’ nephrology.

Abatacept for lupus nephritis: no improvement in one year remission rate but faster falls in proteinuria and effects on serologic markers

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- Over a third of systemic lupus erythematosus (SLE) patients have kidney involvement (lupus nephritis), and are at risk of end-stage renal disease and premature death. Current therapies are toxic and not routinely effective, so novel therapy options are urgently needed. 

Shedding a new light: The implication of microRNAs in chronic kidney disease

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  -- Development of disease is often related to the deregulation of a gene program controlled at the post-transcriptional level by microRNAs (miRNAs). A new review [1], published in Nephrology Dialysis Transplantation during this week’s ERAEDTA Congress in Copenhagen, shows that miRNAs are potential innovative biomarkers, and are promising as groundbreaking drugs. “The review of Laurent Metzinger and colleagues summarizes the current state of art of the research on miRNAs in kidney disease”, explains Professor Denis Fouque, editor-in-chief of Nephrology, Dialysis, Transplantation (NDT). 

Lanreotide ineffective against familial cystic kidney disease

[PRESSWIRE] Copenhagen, Denmark - 25 May, 2018  --  4-6 million people worldwide are affected by familial cystic kidney disease, the most common inherited kidney disease – accounting for ∼10% of European patients on dialysis or living with a kidney transplant. The range of potential therapies is still limited, so other novel therapy options are urgently needed.